GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Diabetic kidney disease (DKD) is one of the most common complications in type 2 diabetes mellitus (T2D) and a major cause of morbidity and mortality in diabetes. Despite the widespread use of nephroprotective treatment of T2D, the incidence of DKD is increasing, and it is expected to become the fift...
Main Authors: | Alba Rojano Toimil, Andreea Ciudin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/17/3955 |
Similar Items
-
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020-06-01) -
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
by: José Luis Górriz, et al.
Published: (2020-03-01) -
GLP-1 Receptor Agonists and Kidney Protection
by: Eulalia Valentina Greco, et al.
Published: (2019-05-01) -
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
by: Qiao Q, et al.
Published: (2016-06-01) -
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
by: Chudleigh RA, et al.
Published: (2020-02-01)